AVLN: Inhaled therapies targeting pulmonary fibrosis show promise for better efficacy and tolerability
The company is advancing three inhaled therapies for pulmonary fibrosis, leveraging a patented nebulizer to address major tolerability barriers and unlock a large underserved market. Lead programs show improved lung exposure and safety, with pivotal data expected next year and strong IP protection…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.